H.C. Wainwright lowered the firm’s price target on Compass Pathways (CMPS) to $45 from $60 and keeps a Buy rating on the shares. The firm says the company’s capital raise in January was more dilutive than expected.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Psychedelic: Relmada acquires neurosteroid from Asarina
- Psychedelic: atai Life Sciences reports BPL-003 study results
- Rising High: Exclusive talk with MSO ETHOS Cannabis
- Compass Pathways appoints Steve Levine as Chief Patient Officer
- Rising High: Exclusive talk with pharmaceutical development company MIRA